For a patient with type 2 diabetes mellitus whose fasting and postprandial glucose levels are consistently 190–350 mg/dL and who was discharged on sliding‑scale insulin alone, is adding a premixed 70/30 insulin (70% NPH, 30% regular) appropriate?

Premixed 70/30 Insulin Is Not Appropriate—Transition to Basal‑Bolus Therapy Immediately

For a patient with type 2 diabetes whose glucose levels consistently range 190–350 mg/dL on sliding‑scale insulin alone, adding premixed 70/30 insulin is explicitly contraindicated; instead, discontinue sliding‑scale monotherapy and initiate a scheduled basal‑bolus regimen with separate long‑acting and rapid‑acting insulins. 1

---

Why Premixed 70/30 Insulin Is Contraindicated

• Premixed insulin (human insulin 70/30) is associated with an unacceptably high rate of iatrogenic hypoglycemia and is not recommended in the hospital. 1
• Randomized trials in hospitalized patients show that premixed insulin produces a 64 % hypoglycemia rate versus 24 % with basal‑bolus therapy, leading to early trial termination. 1
• The fixed 70:30 ratio of intermediate‑acting to short‑acting insulin cannot be adjusted independently, increasing hypoglycemia risk when meal intake varies. 1
• Major diabetes guideline societies (American Diabetes Association, European Association for the Study of Diabetes) explicitly advise against the use of premixed insulin in hospital settings because of the excessive hypoglycemia risk. 1
• Premixed insulin requires twice‑daily injections (before breakfast and dinner) and mandates consistent meal timing and carbohydrate intake, limiting its suitability for patients with variable eating patterns. 1

---

Why Sliding‑Scale Insulin Alone Is Inadequate

• Sliding‑scale insulin as monotherapy is condemned by all major diabetes guidelines because it treats hyperglycemia reactively after it occurs rather than preventing it, leading to dangerous glucose fluctuations. 1
• Only ≈38 % of patients achieve mean glucose < 140 mg/dL with sliding‑scale alone, versus ≈68 % with a scheduled basal‑bolus regimen. 1
• Sliding‑scale insulin provides no basal insulin to suppress hepatic glucose production between meals and overnight, resulting in persistent fasting hyperglycemia. 1
• It also lacks scheduled prandial insulin, causing post‑prandial spikes that are later corrected with large reactive doses, creating a cycle of hyperglycemia → large correction → hypoglycemia → rebound hyperglycemia. 1

---

Recommended Basal‑Bolus Regimen

Initial Dosing

• Discontinue sliding‑scale insulin as the sole regimen immediately and transition to a scheduled basal‑bolus approach. 1
• For glucose levels consistently 190–350 mg/dL, start with a total daily insulin dose of 0.3–0.5 U/kg/day, split 50 % as basal insulin (once daily) and 50 % as prandial insulin (divided among three meals). 1, 2
• Basal insulin: Use a long‑acting analog (glargine, detemir, or degludec) at ≈0.15–0.25 U/kg once daily (e.g., 10–20 U for a 70‑kg patient). 1, 2
• Prandial insulin: Use rapid‑acting insulin (lispro, aspart, or glulisine) at ≈4 U before each of the three largest meals, administered 0–15 minutes before eating. 1, 2
• Correction insulin: Add 2 U for pre‑meal glucose > 250 mg/dL and 4 U for glucose > 350 mg/dL, in addition to scheduled prandial doses. 1, 3

Titration Protocol

• Basal insulin: Increase by 4 U every 3 days if fasting glucose ≥ 180 mg/dL; increase by 2 U every 3 days if fasting glucose is 140–179 mg/dL. Target fasting glucose 80–130 mg/dL. 1, 2
• Prandial insulin: Increase each meal dose by 1–2 U every 3 days based on 2‑hour post‑prandial glucose. Target post‑prandial glucose < 180 mg/dL. 1, 2
• If hypoglycemia occurs (glucose < 70 mg/dL), reduce the implicated insulin dose by 10–20 % immediately. 1, 2

---

Monitoring Requirements

• Daily fasting glucose to guide basal insulin adjustments. 1, 2
• Pre‑meal glucose before each meal to calculate correction doses. 1, 2
• 2‑hour post‑prandial glucose after each meal to assess prandial adequacy. 1, 2
• Bedtime glucose to evaluate overall daily pattern. 1, 2
• Reassess insulin doses every 3 days while actively titrating. 1, 2

---

Expected Clinical Outcomes

• With a properly implemented basal‑bolus regimen, ≈68 % of patients achieve mean glucose < 140 mg/dL, versus ≈38 % with sliding‑scale alone. 1
• Basal‑bolus therapy does not increase hypoglycemia incidence when titrated according to protocol, unlike inadequate or sliding‑scale regimens. 1
• HbA1c reductions of 2–3 % are achievable within 3–6 months with intensive insulin titration. 1, 2

---

Critical Pitfalls to Avoid

• Do not add premixed 70/30 insulin to a patient with glucose levels 190–350 mg/dL; the fixed ratio and high hypoglycemia risk make it unsuitable. 1
• Do not continue sliding‑scale insulin as monotherapy when glucose repeatedly exceeds 180 mg/dL; it is inferior and unsafe. 1
• Do not delay adding prandial insulin when basal insulin alone fails to achieve target fasting glucose. 1, 2
• Never use rapid‑acting insulin at bedtime as a sole correction dose, as it markedly raises nocturnal hypoglycemia risk. 1, 2

---

Hypoglycemia Management

• Treat any glucose < 70 mg/dL immediately with 15 g of fast‑acting carbohydrate (e.g., 4 glucose tablets or 4 oz juice), recheck in 15 minutes, and repeat if needed. 1, 2
• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20 % before the next administration. 1, 2

---

Adjunctive Therapy

• Continue metformin at the maximum tolerated dose (up to 2,000–2,550 mg daily) when adding insulin; metformin reduces total insulin requirements by 20–30 % and provides superior glycemic control. 1, 2
• Discontinue sulfonylureas when initiating basal‑bolus insulin to avoid additive hypoglycemia risk. 1, 2